Brief: Cstone Pharmaceuticals & Pharmalink Enter Into Strategic Partnership For Sugemalimab
21/11/2024 24:58
Nov 21 (Reuters) - CStone Pharmaceuticals 2616.HK :
* CSTONE & PHARMALINK ENTER INTO STRATEGIC PARTNERSHIP FOR
SUGEMALIMAB IN MIDDLE EAST, NORTH AFRICA REGION & SOUTH AFRICA
* UNDER PARTNERSHIP PHARMALINK WILL GAIN COMMERCIAL RIGHTS
FOR
SUGEMALIMAB IN MIDDLE EAST, OTHERS
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026